STERIS Fiscal Q1 2027 Earnings: Revenue Rises 7% While Free Cash Flow Falls

STERIS (NYSE: STE) reported fiscal Q1 2027 revenue of $1.5 billion for the quarter ended June 30, 2026, up 7% year over year, while GAAP diluted EPS increased to $2.04 from $1.79. Adjusted EPS rose to $2.59, but free cash flow declined as working capital contributed less than a year earlier; Healthcare services and consumables were the main operating growth drivers.

Core Results

Reported revenue increased 7%, while constant-currency organic revenue grew 6%. The organic measure excludes currency movements and significant acquisitions and divestitures, providing a view of underlying business growth.

Both GAAP and adjusted earnings increased faster than revenue. Cash generation moved in the opposite direction, however, with operating cash flow and free cash flow declining despite higher net income.

Adjusted net income and EPS are non-GAAP measures that exclude items including acquired intangible asset amortization, restructuring charges and certain acquisition-related costs.

Segment Performance

Healthcare remained STERIS’s largest segment and contributed most of the company’s revenue increase. Life Sciences recorded the highest reported and organic growth rates, while AST’s capital equipment revenue declined.

Healthcare service revenue grew 10% and consumables increased 9%, compared with a 1% increase in capital equipment. Management attributed the segment’s higher operating income to volume, pricing, productivity and favorable mix, partially offset by inflation and higher tariff costs.

AST service revenue increased 6%, but capital equipment declined 13%. Better pricing supported operating income, while higher depreciation and labor costs limited the improvement.

Life Sciences capital equipment revenue rose 17%, consumables increased 8% and services grew 2%. Pricing and volume lifted operating income, partly offset by inflation and lower productivity.

Higher Earnings Did Not Translate Into Higher Cash Flow

Operating cash flow fell to $367.1 million even as GAAP net income increased to $200.1 million. STERIS attributed the divergence primarily to a significantly smaller working-capital contribution than in the prior-year quarter, with higher net income providing only a partial offset.

Free cash flow declined by approximately 14.4% to $279.6 million. This cash-flow movement is important because STERIS is beginning a multi-year manufacturing and distribution investment that will require additional capital spending.

Chemistries Consolidation Raises Near-Term Costs and Capital Needs

STERIS announced a targeted restructuring plan tied to a new Formulated Chemistries Center of Excellence in North Carolina. The plan is expected to consolidate U.S. chemistries manufacturing and distribution and includes the anticipated closure of facilities in St. Louis, Missouri, and Plymouth, Minnesota.

The company expects total pretax restructuring charges of approximately $55 million to $70 million. That includes an estimated $40 million to $50 million of cash expenditures for employee retention, severance, benefits, transition and facility-exit costs, plus $15 million to $20 million of non-cash charges primarily related to accelerated depreciation.

Charges will be incurred over time, with completion anticipated during fiscal 2030, and will be excluded from adjusted earnings. STERIS expects the project to expand capacity, accelerate innovation and optimize its U.S. network, but the estimated costs and timeline remain subject to revision as implementation progresses.

Fiscal 2027 Capital and Cash Flow Outlook

The North Carolina investment led STERIS to raise its capital expenditure outlook by $75 million and lower its free cash flow outlook by $50 million. Management said the first-quarter cash result would partially offset the additional capital spending.

Recent Insider Transactions

The supplied six-month insider summary reported 58,255 shares classified as purchases across 12 transactions and 10,426 shares sold across four transactions, producing net purchases of 47,829 shares. These classifications should not be treated as evidence of open-market buying because the transaction list includes stock awards and the exercise of derivative securities.

Risks Investors Should Monitor

• Tariff and inflation pressure: Both factors partially offset Healthcare’s operating improvement, creating a continuing risk to segment profitability.
• Working-capital volatility: A smaller working-capital contribution caused operating cash flow to decline despite higher earnings, showing that profit growth may not translate directly into cash generation.
• Restructuring execution: The chemistries consolidation extends through fiscal 2030 and carries estimated pretax charges of $55 million to $70 million. Actual costs and timing could change.
• Uneven equipment demand: AST capital equipment revenue fell 13%, contrasting with service growth and stronger equipment performance in Life Sciences.
• Higher capital requirements: The increased capital spending outlook has already reduced the company’s fiscal 2027 free cash flow outlook.

Summary

STERIS’s fiscal Q1 2027 results combined 7% revenue growth with higher GAAP and adjusted earnings, led primarily by Healthcare services and consumables. The main counterweight was weaker cash conversion due to working capital, while the North Carolina chemistries project will increase capital spending and restructuring costs over several years. Future results will depend on sustaining segment growth while managing tariffs, inflation, working capital and consolidation execution.